Review of 11 national policies for rare diseases in the context of key patient needs

Orphanet Journal of Rare Diseases

Volumn 12, Issue 1, 2017, Pages

  Dharssi, Safiyya ^a   Wong Rieger, Durhane ^b   Harold, Matthew ^a   Terry, Sharon ^c  

^a PFIZER INC   (United States)

^b Canadian Organization for Rare Disorders   (Canada)

^c GENETIC ALLIANCE   (United States)

Author keywords

Asia; Europe; Legislation; National rare disease plan; North America; Patient advocacy; Policy; South America

Indexed keywords

ARGENTINA; BRAZIL; BULGARIA; CANADA; CHINA; CLINICAL RESEARCH; DIAGNOSTIC PROCEDURE; FRANCE; GERMANY; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; MEXICO; PATIENT ADVOCACY; PATIENT EDUCATION; PUBLIC HEALTH CAMPAIGN; RARE DISEASE; REVIEW; SUPPORT GROUP; TAIWAN; TURKEY (REPUBLIC); UNITED KINGDOM; DRUG LEGISLATION; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

HEALTH POLICY; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; RARE DISEASES; UNITED STATES;

EID: 85016644748     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-017-0618-0     Document Type: Review

References (69)

1. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3-4):163-72.
2. Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821-5.
3. Orphan Drug Act, Public Law 97-414. 97th Congress. January 4, 1983 (US).2049-2066.
4. Orphan Drug amendments of 1985, Public Law 99, 91, 15 August 1985 (US).
5. Orphan Drug amendments of 1988, Public Law 100-290, 18 April 1988 (US).
6. Diseases. Genetic and Rare Diseases Information Center (GARD) https://rarediseases.info.nih.gov/gard/browse-by-first-letter/. Accessed 08 Aug 2016.
7. European Commission. DG Health and Food Safety. Public Health. Rare diseases policy. https://ec.europa.eu/health/rare_diseases/policy_en. Accessed 17 Feb 2017.
8. Passos-Bueno MR, Bertola D, Horovitz DD, de Faria Ferraz VE, Brito LA. Genetics and genomics in Brazil: a promising future. Mol Genet Genomic Med. 2014;2(4):280-91.
9. Taiwan Foundation for Rare Diseases. About Rare Diseases: Rare Diseases in Taiwan. 2004; http://www.tfrd.org.tw/english/rare/cont.php?kind_id=16&top1=About%20rare%20diseases&top2=Rare%20Diseases%20in%20Taiwan. Accessed 17 Feb 2017.
10. Council of the European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Off J Eur Union. 2009;151:7-10.
11. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039-41.
12. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964-79.
13. Wastfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260(1):1-10.
14. Dunoyer M. Accelerating access to treatments for rare diseases. Nat Rev Drug Discov. 2011;10(7):475-6.
15. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4):267-8.
16. EURORDIS Rare Diseases Europe. About Rare Diseases. http://www.eurordis.org/about-rare-diseases. Accessed 08 Aug 2016.
17. Villa S, Compagni A, Reich MR. Orphan drug legislation: lessons for neglected tropical diseases. Int J Health Plann Manage. 2009;24(1):27-42.
18. History of Leadership. https://rarediseases.org/about/what-we-do/history-leadership/. Accessed 08 Aug 2016.
19. French National Plan for Rare Diseases 2005-2008: "Ensuring equity in the access to diagnosis, treatment and provision of care". 2004; http://www.orpha.net/actor/EuropaNews/2006/doc/French_National_Plan.pdf. Accessed 17 Feb 2017.
20. 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases. Part I: Overview of Rare Disease Activities in Europe. 2012; http://www.eurordis.org/sites/default/files/2012ReportStateofArtRDActivitiesPart%201.pdf. Accessed 17 Feb 2017.
21. EUROPLAN 2012-2015. European Project for Rare Diseases National Plans Development http://www.europlanproject.eu/Content?folder=1&content=1. Accessed Aug 08 2016.
22. Communication from the commission to the European parliament, the council, the European economic and social committee and the committee of the regions on rare diseases: Europe’s challenges. Commission of the European Communities 2008; COM(2008) 679 final:http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf. Accessed 15 Feb 2017.
23. The European Union Committee of Experts on Rare Diseases (EUCERD). 2014; http://www.eucerd.eu/. Accessed 17 Feb 2017.
24. Commission Decision: Setting up a commission expert group on rare diseases and repealing Decision 2009/872/EC. Off J Eur Union. 2013; (2013/C 219/04):https://ec.europa.eu/health/sites/health/files/rare_diseases/docs/dec_expert_group_2013_en.pdf. Accessed 15 Feb 2017.
25. Forman J, Taruscio D, Llera VA, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012;101(8):805-7.
26. Rodwell C, Aymé S. 2014 Report on the State of the Art of the Rare Disease Activities in France. 2014. http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesFR.pdf.
27. Evangelista T, Hedley V, Atalaia A, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis. 2016;11(1):17.
28. Delivering for patients with rare diseases: Implementing a strategy. A report from the UK Rare Disease Forum. 2016; 1-45. Available at: http://www.raredisease.org.uk/media/1803/ukrarediseaseforum-progress-report-2016.pdf. Accessed 10 Nov 2016.
29. European Reference Networks. Networks implementation. Call for applications 2016. 2016; https://ec.europa.eu/health/ern/implementation/call_en. Accessed 15 Feb 2017.
30. Tseng M. The Progress of Policies on Rare Diseases in Taiwan. National Taipei University Taiwan Foundation for Rare Disorders.
31. Orphanet Activity Report. OrphaNews, The Newsletter of the Rare Diseases Community. 2016; http://www.orpha.net/actor/EuropaNews/2016/160524.html. Accessed 10 Nov 2016.
32. Cibersalud. Republic Argentina. Presidency of the Nation. 2016; http://www.cibersalud.gob.ar/. Accessed 10 Nov 2016.
33. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65(4):281-393.
34. Evaluation of population newborn screening practices for rare disorders in Member States of the European Union. Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA Countries. 2012; http://ec.europa.eu/chafea/documents/news/Report_NBS_Current_Practices_20120108_FINAL.pdf. Accessed 15 Feb 2017.
35. Harms E, Olgemoller B. Neonatal screening for metabolic and endocrine disorders. Dtsch Arztebl Int. 2011;108(1-2):11-21. quiz 22.
36. Newborn Screening Program: Disordered Screened. Perinatal Services BC. An agency of the Provincial Health Services Authority. 2016; http://www.perinatalservicesbc.ca/our-services/screening-programs/newborn-screening-program/disorders-screened. Accessed 10 Nov 2016.
37. Portal da Saude. Blood collection. Ministry of Health. 2016; http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/secretarias/1083-sas-raiz/dahu-raiz/programa-nacional-de-triagem-neonatal/l2-programa-nacional-de-triagem-neonatal/26162-coleta-de-sangue. Accessed 15 Feb 2017.
38. Survey of the Delay in Diagnosis for 8 Rare Diseases in Europe (‘EURORDISCARE 2’). Fact sheet. Available at: http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_Eurordiscare2.pdf. Accessed 19 Oct 2016.
39. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Off J Eur Commun. 2000; 22. 1. 2000:http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. Accessed 15 Feb 2017.
40. Orphan designation. European Medicines Agency: Science Medicines Health. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp. Accessed 10 Nov 2016.
41. PRIME: priority medicines. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/regulation/general/general_content_000660.jsp%26mid%3DWC0b01ac058096f643. Accessed 12 Dec 2016.
42. China to reform drug approval system to expedite authorisation of innovative drugs. IHS Markit. 2015; https://www.ihs.com/country-industry-forecasting.html?ID=1065999174. Accessed 31 Oct 2016.
43. Regulatory Initiative: Regulations Amending the Food and Drug Regulations - Orphan Drugs - Forward Regulatory Plan 2016-2018. Health Canada. 2016; http://www.hc-sc.gc.ca/ahc-asc/legislation/acts-reg-lois/frp-ppr/2016-2018/odrd-momr-eng.php. Accessed 31 Oct 2016.
44. Tsai Y-W. Access to orphan drugs through a HTA framework: Rare Disease Legislation in Taiwan. 7th Asia Pacific Future Trends Forum; 2014; Malaysia.
45. Caetano PA. Expedited approval of orphan drugs in Latin America not yet a reality. 2011.
46. Upadhyaya S. Highly Specialised Technology Evaluations at NICE. UK: Chilean Ministry for Health; 2016.
47. Fund for new medicines doubles. 2015; http://news.scotland.gov.uk/News/Fund-for-new-medicines-doubles-18eb.aspx. Accessed 16 Aug 2016.
48. Rodwell C, Aymé S. 2014 report on the state of the art of the rare disease activities in Bulgaria. 2014. http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesBG.pdf.
49. Communication Tools. http://www.alliance-maladies-rares.org/les-outils-de-communication/#more-2869. Accessed 08 Aug 2016.
50. Rare Disease Day 2016. 2016; http://www.raredisease.org.uk/our-work/rare-disease-day-2016/#. Accessed 08 Aug 2016.
51. Miteva-Katrandzhieva TIG, Stefanov R, Naumova E, Guergueltcheva V, Savov A. Overview of epidemiological rare diseases registries in Bulgaria. Rare Dis Orphan Drugs. 2016;3(1):11-5.
52. Health Canada. Drugs and health products. guidance for industry - priority review of drug submissions. 2009. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/priorit/priordr-eng.php. Accessed 17 Feb 2017.
53. Wong-Rieger D. State of the art of rare disease activities around the world: overview of the non-European landscape. Orphanet J Rare Dis. 2012;7:(Suppl: A2).
54. Rodwell C, Aymé S. 2014 report on the state of the art of rare disease activities in Germany. 2014. http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesDE.pdf.
55. European Commission. Research & Innovation. Key Research Areas: Rare Diseases. https://ec.europa.eu/research/health/index.cfm?pg=area&areaname=rare. Accessed 15 Feb 2017.
56. European Commission. Horizon 2020: The EU Framework Programme for Research and Innovation. https://ec.europa.eu/programmes/horizon2020/. Accessed 15 Feb 2017.
57. Bouslouk M. G-BA benefit assessment of new orphan drugs in Germany: the first five years. Expert Opin Orphan Drugs. 2016;4(5):453-5.
58. Cui Y, Zhou X, Han J. China launched a pilot project to improve its rare disease healthcare levels. Orphanet J Rare Dis. 2014;9:14.
59. Choquet R, Landais P. The French national registry for rare diseases: an integrated model from care to epidemiology and research. Orphanet J Rare Dis. 2014;9(1):O7.
60. European Platform for Rare Diseases Europe (EpiRare). 2011; http://www.epirare.eu/project3.html. Accessed 14 Nov 2016.
61. NICE highly specialised technologies guidance. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance. Accessed 19 Oct 2016.
62. £40 m for new medicines. 2014; News. Available at: https://www.wired-gov.net/wg/news.nsf/articles/40m+for+new+medicines+08102014081000?open. Accessed 19 Oct 2016.
63. Sutton P. Northern Ireland brings secure funding for rare disease drugs a step closer. Muscular Dystrophy UK Registered Charity 2015; News article. Available at: http://www.musculardystrophyuk.org/news/news/northern-ireland-brings-secure-funding-for-rare-disease-drugs-a-step-closer/. Accessed 19 Oct 2016.
64. EUCERD. Recommendations on core indications for rare disease national plans/strategies. 2013. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_Indicators_adopted.pdf. Accessed 15 Feb 2017.
65. Now is the Time: A Strategy for Rare Diseases is a Strategy for all Canadians. Executive Summary: Canada’s Rare Disease Strategy 2015; https://www.raredisorders.ca/content/uploads/Exec-RD-Strategy-Summary-FINAL-EN.pdf. Accessed 08 Aug 2016.
66. The UK Strategy for Rare Diseases. 2013; https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_Rare_Diseases.pdf. Accessed 08 Aug 2016.
67. EURORDIS Position Paper. Patients’ priorities and needs for rare disease research 2014-2020. 2011. http://www.eurordis.org/sites/default/files/publications/what_how%20_are_disease_research_0.pdf. Accessed 08 Aug 2016.
68. Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002.
69. Feltmate K, Janiszewski PM, Gingerich S, Cloutier M. Delayed access to treatments for rare diseases: who’s to blame? Respirology. 2015;20(3):361-9.